92 -4 (32/2) 2020 — Ziyaeva D.F., Kosimov Z.O. — ALGORITHM FOR CHOICE OF ANTIHYPERTENSIVE THERAPY IN METABOLIC SYNDROME AND ARTERIAL HYPERTENSION

ALGORITHM FOR CHOICE OF ANTIHYPERTENSIVE THERAPY IN METABOLIC SYNDROME AND ARTERIAL HYPERTENSION

Ziyaeva D. F. -Andijan State Medical Institute

Kosimov Z. O. -Andijan State Medical Institute

Parpieva S. B. -Andijan State Medical Institute

Resume

In the past two decades, the concept of the role and functions of adipose tissue has changed, which is now considered not only as an organ of endocrine regulation of energy balance, but also as an integral link between the formation of metabolic disorders and cardiovascular pathology.

Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers belong to the main classes of antihypertensive drugs used in the treatment of hypertension in patients with metabolic syndrome. Each of the representatives of this group has clinical and pharmacological features and nuances of clinical use. Based on their analysis, an algorithm for the differentiated choice of a specific drug is proposed.

Key words: antihypertensive drugs, inflammation, metabolic syndrome.

First page

372

Last page

375

For citation: Ziyaeva Dilyaram Fayzirakhmanovna, Kosimov Zafarbek Odiljon Ugli, Parpieva Salimakhon Bakizhanovna, Algorithm for choice of antihypertensive therapy in metabolic syndrome and arterial hypertension//New Day in Medicine 4(32)2020 372-375

List of References

1. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мальто А.С. Мочевая кислота – ключевой компонент кардиоренометабо- лического континуума // Кардиоваскулярная терапия и про­филактика 2008. №4.95-106.
2. Кузьмина Е.Р., Морозова Т.Е. Влияние антитиертензивной терапии на маркеры воспаления и инсулинорезистентности у больных артериальной тиертонией с метаболическим синд­ромом // Врач-аспирант. – 2014. – № 4.3 (65). – С. 388- 394.
3. Латыйпова Е.Р., Морозова Т.Е. Активность С-реактивною белка у мужчин и женщин, страдающих артериальной гипер­тензией в сочетании с метаболическим синдромом, под вли­янием небиволола // Сборник материалов XX Российского национального кошресса “Человек и лекарство”, 15-19 апре­ля 2013. -С.91.
4. Boden-Albala B, Suzuki T, Hirata K et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS). Am Heart J., 2008, Aug. 156 (2): 405-10.
5. Gress TW, Nieto FJ, Shahar E et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med, 2000, 342: 905-912.
6. Sharma AM, Pischon T, Hardt S et al. Hypothesis: beta-adrenergic receptor blockers and weight gain: systematic analysis. Hypertension, 2001, 37: 250-254.
7. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr. Med. Res. Opin., 2010, Mar. 26 (3): 615-29.